Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 January 2021 | Story Charlene Stanley | Photo Charlene Stanley
Dr Matteo Grilli with his first book in front of the North Block on the Bloemfontein Campus.
Dr Matteo Grilli from the International Studies Group (ISG) became the second ISG scholar in just four years to receive a coveted P-rating from the NRF.

A P-rating (Prestigious Awards) by the National Research Foundation (NRF) is the holy grail for all young researchers at all South African universities and across all disciplines. It is a valuable tool for benchmarking local researchers against the best in the world. But it is hard to come by. Only one or two researchers are normally granted this sought-after standing each year. 

Dr Matteo Grilli, a young Italian historian from the International Studies Group (ISG), says he was “pleasantly surprised” when he recently got the nod from the NRF, attributing his P-rating to the “excellent training and support” that he received from the UFS, and specifically the ISG and its head, Prof Ian Phimister.  

Unique achievement for ISG
What makes this achievement even more significant, is that the ISG produced another P-rated scholar a mere four years ago (Dr Daniel Spence in 2016).

“For Prof Phimister to produce two P-rated researchers in such a short time is really an unbelievable achievement. I am not aware of any other department at any South African university that could achieve this,” says Dr Glen Taylor, Senior Director: Research Development. 

P-rating requirements
The NRF’s P category honours young researchers (normally younger than 35 years) who have held a doctorate or equivalent qualification for less than five years. Researchers in this group are recognised by all or the vast majority of reviewers as having demonstrated the potential to become future international leaders in their field based on exceptional research performance and output from their doctoral and/or early postdoctoral research careers.

UFS becoming a mecca for African studies
Dr Grilli produced his first book, Nkrumaism and African Nationalism: Ghana's Pan-African Foreign Policy in the Age of Decolonisation around two years ago, after being accepted as a postdoc scholar by the ISG in 2015.

This unique research centre was established towards the end of 2012, with the aim of attracting and recruiting high-calibre postgraduate students and postdoctoral fellows from all over the world to the UFS. 

“Working at the ISG has undoubtedly been the best experience of my life and made me the solid scholar I am today. At the ISG, I found the best working environment you could possibly have in an academic setting, even compared to the Northern Hemisphere,” Dr Grilli says.

He believes the centre’s strength lies in the “exceptional exchange” that researchers have with their peers, allowing them to not only master their research subject but also to learn from other members’ research and methodologies.

“In my view, the ISG is concretely contributing to bringing the centre of African studies back to the African continent,” he enthuses.

Passion for Southern African politics
Dr Grilli specialises in the political history of Ghana and Southern Africa, focusing on transnational histories of African liberation movements, the history of Pan-Africanism, the Cold War and decolonisation in Africa, and the history of European migrations in sub-Saharan Africa (particularly Italian communities in Ghana and the Congo DRC). 

He is currently working on a book project about the history of Pan-Africanism, Socialism, and Nationalism in Southern Africa, particularly in Lesotho, eSwatini, and Botswana.

Asked what advice he had for young researchers, he echoes the counsel he received from Prof Phimister at the start of his tenure at the ISG: 

“Always aim high. Don’t be intimidated by the fact that there is a lot of competition in the academia, nor that you might be disadvantaged because you work in the Global South. If you work hard, your research will speak for itself and you will be able to publish solid works even in the most prestigious journals of the Northern Hemisphere.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept